Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MABp1 in Type 2 Diabetes
NCT01427699Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2011
- Primary completion
- Oct 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bermekimab in type 2 diabetes mellitus (T2DM), sponsored by Janssen Pharmaceutical. Primary endpoint: Safety and Tolerability at 90 days. Started Jun 2011; status: completed.
02
Drugs
bermekimab
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01427699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01427699.